

Supplementary Materials for
Transcriptional determinants of lipid mobilization in human adipocytes

Alison C. Ludzki *et al.*

Corresponding author: Mikael Rydén, mikael.ryden@ki.se; Niklas Mejhert, niklas.mehjert@ki.se

Sci. Adv. **10**, eadi2689 (2024)
DOI: 10.1126/sciadv.adi2689

This PDF file includes:

Figs. S1 to S5
Tables S1 to S4

Fig. S1.





Fig. S1. Validation of the adipocyte screening system. **(A)** Representative Western blots of PLIN1 and Lamin A/C protein content for differentiated adipocytes transfected with non-targeting control (siC) or *PLIN1* siRNA (siP) ($n = 2$). **(B)** Glycerol release from siP vs. siC cells. *** $P < 0.001$ for a main effect for siRNA from a two-way ANOVA ($n = 3$). Bar plots in panel B are presented as mean \pm SEM. **(C)** Hits from the siRNA screen were re-screened on a separate adipose tissue biopsy (“Re-screen”). **(D)** LDH activity z-scores for screen hits. The dashed line marks a z-score ± 3 .


Fig. S2.

A



B

Waist-to-hip ratio



HOMA-IR




Fig. S2. Clinical parameters. (A) Subject characteristics for the clinical cohort for lipolysis measurements with median and interquartile range ($n = 12$). (B) Forest plot displaying correlations and effects for meta-analysis of *ZNF189* expression in subcutaneous adipose tissue from 7-9 published human cohorts.

Fig. S3.





Fig. S3. Quality control of the *ZNF189* knockdown in fat cells. (A) Quantitation of the Western blots presented in Figure 3A-B. Nuclear enrichment is calculated vs. cytosolic fraction. (B) Gene expression of adipocyte marker genes. (C) Stimulated lipolysis validation experiments for *ZNF189* depletion using siRNA from two independent vendors. (D) Gene expression of lipolytic regulator genes. *siC* = control cells, *siZ* = *ZNF189* depleted cells. Data are mean \pm SEM. In all panels, replicates are highlighted by dots and are based on at least three independent experiments. ** $P < 0.01$, *** $P < 0.001$ for Welch's t-test assuming unequal variance (A), or Tukey's multiple comparison's (C).

Fig. S4.

A



B




Fig. S4. Quality control of the functional genomics assays. (A) Heatmap for CUT&Tag peaks from siControl (siC) and siZNF189 (siZ) cells analyzed by edgeR with an adjusted P value < 0.05 set as the threshold for up- and down-regulated peaks ($n = 3$). (B) ChIP qPCR validation of the ChIP sequencing experiment ($n = 1$). Neg = negative control locus, 3kb downstream of ZNF189 ChIPseq *PDE1B* peak. Pos = positive control region from the ZNF189 ChIPseq.

Fig. S5.




Fig. S5. *PDE1B* regulation in human adipocytes. (A) Gene expression (left and middle plots) and glycerol release (right plot) measures from control cells and *ZNF189* overexpressing (OE) adipocytes. Glycerol release was measured over three hours under basal (non-stimulated) conditions as well as following incubation with isoprenaline. (B) cGMP levels in cells overexpressing *PDE1B2* under a doxycycline (doxy)-inducible promoter. (C) cGMP levels in adipocytes treated with nontargeting control (siC) or *ZNF189* siRNA (siZ). Isoprenaline concentrations were 1-10 μ M. Data are mean \pm SEM. In all panels, replicates are highlighted by dots and are based on at least three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 for a one-tailed (A) or two-tailed (B) t-test. Glycerol data in (A) were analyzed by two-way ANOVA, results from post-hoc statistical analyses are indicated.

Table S1.

Parameter 1	Parameter 2	r	P
Replicate 1	Replicate 2	0.88	1.16E-243
Replicate 1	Replicate 3	0.89	7.15E-250
Replicate 2	Replicate 3	0.89	8.43E-251

Pearson correlation statistics for lipolysis screen replicates.

Table S2.

Gene ID	Glycerol (z-score)	Adj. P
<i>UBB</i>	25.48	1.00E-13
<i>STK16</i>	19.59	1.00E-13
<i>NAA15</i>	17.16	1.00E-13
<i>PLRG1</i>	14.45	1.00E-13
<i>SUPT6H</i>	12.80	1.00E-13
<i>KLF2</i>	11.05	1.00E-13
<i>LRCH4</i>	10.22	1.00E-13
<i>ARID5B</i>	9.26	1.00E-13
<i>ZMIZ2</i>	9.16	1.00E-13
<i>ARID1B</i>	9.15	1.00E-13
<i>KLF7</i>	7.03	1.07E-05
<i>JUNB</i>	6.89	2.05E-13
<i>PLIN1</i>	6.85	1.00E-13
<i>MTPN</i>	6.74	1.61E-11
<i>HMGN1</i>	6.73	2.52E-11
<i>SMAD4</i>	6.67	1.27E-10
<i>TGS1</i>	5.98	9.28E-08
<i>ASB8</i>	5.58	1.45E-10
<i>JUN</i>	4.90	2.74E-05
<i>EPC1</i>	4.72	1.13E-05
<i>TCERG1</i>	4.69	1.70E-05
<i>CLPB</i>	4.51	5.66E-05
<i>ANKRD54</i>	4.26	9.67E-09
<i>PTRF</i>	4.23	3.72E-05
<i>HDAC7</i>	2.07	4.26E-05
<i>TDG</i>	-3.54	1.35E-02
<i>ZMYND8</i>	-3.58	6.51E-04
<i>HIRA</i>	-3.73	4.03E-02
<i>REXO4</i>	-3.81	1.77E-05
<i>SRCAP</i>	-3.89	7.99E-04
<i>LASS4</i>	-4.01	2.37E-02
<i>C19orf2</i>	-4.23	9.80E-04
<i>ZNF326</i>	-4.64	1.44E-02
<i>EDF1</i>	-4.70	9.35E-04
<i>TSC22D1</i>	-4.72	3.13E-04
<i>ZNF189</i>	-5.09	2.12E-05
<i>SMAD5</i>	-5.73	2.34E-12
<i>LMCD1</i>	-5.92	2.85E-04
<i>SMAD1</i>	-6.98	1.61E-09

Lipid mobilization screen hits. Adj. *P* from Dunnett's *posthoc* test after a One-way ANOVA.

Table S3.

Protein	Normalized intensity (median)	Enrichment (intensity in ZNF189 IP/intensity in IgG)
ZNF189	3.97	15.67
SUMO2	2.94	7.13
CCAR2	2.00	4.01
XRCC6	1.75	5.94
TRIM28	1.63	6.00
ZMYM4	1.52	2.86
SUMO1	1.29	3.08
GTF2I	1.01	2.02
AHNAK	0.85	16.37
ALDH18A1	0.69	1.61
ADNP	0.67	1.59
SLC25A3	0.38	1.30
ZBED3	0.29	1.22
EML1	-0.27	0.83
SAMHD1	-0.28	3.14
PC	-0.45	6.26
RPL7	-0.61	4.44
BLMH	-2.63	0.16

ZNF189 interacting proteins identified by Immunoprecipitation-Mass Spectrometry. Interacting proteins were selected after quantification by filtering to include proteins with no detection in IgG samples or enrichment (fold change *versus* IgG) > 3 (n = 4).

Table S4.

Gene	Forward primer (5'-3')	Reverse primer (5'-3')
<i>I8S</i>	TGACTCAACACGGAAACC	TCGCTCCACCAACTAAGAAC
<i>ADIPOQ</i>	GGTCTCGAACTCCTGGCCTA	TGAGATATCGACTGGGCATGGT
<i>ANKRD54</i>	AGATCATCCAT ATGCTGAGG	TCTTGTTGTA CTTGTCATCTG
<i>ARID1B</i>	ATGGA ACTAGATCTAACCTC	CTGGTAAACATTGATGGTCTTC
<i>ASB8</i>	TTCTAGTCCGGTAAACAGAG	CTCCAAACTGCCGAATTG
<i>B2M</i>	AAGGACTGGTCTTCTATCTC	GATCCCAC TTA ACTATCTTGG
<i>CEBPA</i>	CCCGGCAACTCTAGTATTAG	AAATGACAAGGCACGATTG
<i>CD36</i>	CAAGTTGTCCCTCGAAGAAGG	CATCATCACTCCTGTGGATT
<i>EDF1</i>	CATTCTATTACCAAGAACACGG	TGGCTTCTCATTGATTTCG
<i>EPC1</i>	CAAAGTCTTACCATCGTCTG	TTCCCTACGGAAAGCAAAG
<i>HIRA</i>	AGGAAGT GATATGACGGTATC	GTGGAAAGTGACGGATTAAAG
<i>JUN</i>	AAAGGATA GTGCGATGTTTC	TAAAATCTGCCACCAATTCC
<i>JUNB</i>	TACTGTGGAAAAGAAACACG	GAACAAACACACACAAACAC
<i>KLF2</i>	AAGGGCCTT AATTGTACTG	ATAAAAAACGAACCAGGTAGC
<i>KLF7</i>	AAAACAAGAAGAGGGTTCAC	ACTTATAAGGCTTCTCACCTG
<i>LMCD1</i>	TGTCAAGCAATATAAGAGCG	CAGACGTATTCCACTTCTTG
<i>LRCH4</i>	ATTTCAGAGCTGTCAATTCC	CTGTCGATGAAGTCAATCTG
<i>LRP10</i>	GATGGAGGCTGAGATTGTG	GAGTCATATCCTGGCGTAAG
<i>NAA15</i>	AAGGATGAATTTCAGCAAGG	CCACCTTTCTTGTCTTG
Neg ctrl-ChIP qPCR	CAACCTGACTGAGATGGATGAG	AAGCTCCCTAACAGAGGAAATG
<i>PDE1B1</i>	GTCCCTCCGGAGATGCTG	AGCAAGAAGATGTGGATTAAGC
<i>PDE1B</i> -all variants	CTTCAAGATCCCCACTGTGTT	GAATCCTTACCAACACAGATC
<i>PDE1B</i> -ChIP qPCR	CTTTCTGCTGACATACTCAACC	GGGATCTGCAATCTTAGATG
<i>PLRG1</i>	ACTATAAAGATCTGGGACTTGG	CAGCATTCACTTGTGTTGTC
Pos ctrl-ChIP qPCR	AGTCCAGCTCTTTGCCTC	GCAGTTCTGAGACGTTAACGA
<i>PPIA</i>	CCCACCGTGTCTTCGACATT	GGACCCGTATGCTTTAGGATGA
<i>PTRF</i>	TCATGATCTACCAGGATGAAG	TCCTCAATAACCTCCTCAAC
<i>REXO4</i>	TGAAGTTGTTCAGAAGGAAG	GTACCTT TAGGT CATTATGCAG
<i>SMAD1</i>	GGCATATTGAAAAGGAGTTC	AGATGCTACTGTCACTAAGG
<i>SMAD5</i>	CCAGTCTTACCTCCAGTATTAG	TCCTAAACTGAACCAGAAGG
<i>SRCAP</i>	CATCTCATGATAGTGACACC	CTTATCTCAACACCTGAG
<i>STK16</i>	GAATGAGATAGAAAGGCTGAAG	ACCCAAGTCCATTAAAAGT
<i>SUPT6H</i>	GAACCTAGAAGAAGAAGCTGAC	CACCTAAAATGCTGATTTC
<i>TCERGI</i>	AGAGGAGATGACTGAAGAAG	CCATGGAGTACCAGGAATAG
<i>TDG</i>	TCAAATGGCTAATTGAGAG	TAAGCATGGCTTCTTCTTC
<i>TGS1</i>	GAACAAAAAGGTGAATGGTC	TCTCTGTCACCTTAATCCC
<i>UBB</i>	CCGCTAACAGGTCAAAATG	TAGTCAGAAAGAGTACGGC
<i>URII</i>	CTTGATAGTAAGCCTGATACTG	GTGTTACGATCTCCTTTCC
<i>ZMIZ2</i>	AGGAATGACACCCTGTATG	ATACACCTCAGAGTAGGTTC
<i>ZMYND8</i>	ACTATATGAAGCAGCCACTC	TCTCACATTCAAGGACAAAC
<i>ZNF189</i>	TCTCACTGGATGTTGAAC	GAAATTGAGGAAGAAGTGGA
<i>ZNF326</i>	CTGCATCTGGAAAGTTCTTC	TACACTCATGCAAAACTCC

ZNF189 DNA gblock sequence:

ctgtctggtagctagegccaccATGGCATCACCATCTCCTCCACCTGAATCAAAGGACTGTTGA
CTTTGAGGACGTAGCGGTCTTACTCAAGAAGAATGGGACTATTGGACCCAG
CTCAAAGGTCTTTACAAAGATGTGATGGAAAATGGAACCTCGTTAC
TTGACGTACTTAACAGGGATAAAGATGAGGAGCCTACCGTTAACAGGAGATCGAG
GAGATTGAAGAGGGAGGTAGAACCCACAGGGTGTATTGAACTCGTGGAGACTCGACA
AATCGACCAGGACCCATGGGTCGAGACATTGAACTCGTGGAGACTCGACA
AACAAAGAGGGATTTCTTGTGGAAATCCCCGGAAAGCCTGACTCAGGAACAG
CGAATGTTAGGGAGAACAAATATCATTAGGAAGAGGCCTAATAGTGAGGAGAA
GTGTCATAAATGCGAGGAATGTGGAAAGGATTGTAAGAAAAGCGCATTATCC
AGCATCAGAGGGTCCACACCGGAGAAAAACCCCTTCAGTGTAAACGAATGCGGAAAA
TCCTTTCACGGAGTTCAATTGTAATAGAACACCAACGCATTCAACCGGGAGAGG
CCATATGAGTGTATTGCGGCAAGACGTTCTGTTCAACATTGATAACCGC
ACCAAAGGATTACACACCGCGAGCGGCCCTATCAATGTAACCAATGTAAGCAGTCA
TTTCTCAGCGCAGGAGCCTGTTAAGCATCAGAGAACACACACCGGGCGAAAAACC
GCATAAAATGTTCAACTGTGGAAAGGCTTCAGTTGGAAGTCCCCTTATCGAAC
TCAGCGGACTCACACCGGCAGAGCCGTACCGTACGAAAGTGAAGAAGAGCT
TTTCTCGCAACAGTTGCTCGTGGAGCATCAACGAATCCACACAGGTGAGCGGCC
ACAAATGTGGGAATGCGGGAAAGCTTCCGGCTAGCACGTATCTCATTGAGCACC
AAAAAAATCCATACGGGAGAGAACCCCTCTGTCATAGAACGAAAGTCCTT
AGCCGGTCCAGTTCTGATAGAGCATCAGCGGATACTGAGTGAAGGCTTAC
CAATGCAAGGAGTGTGGAAAAAGCTTAGTCAACTGTGCAACTTGACCCGACACCA
GAGGATTCACACAGGTGATAAACACATAAGTGCAGAACATGCGGAAAGCTTTA
GCCGATCTCCGGCCTGATCCAACATCAGAGAACATCCACACGCGAGAGAACATAC
CCGTACAATGAAACTAAAGAACATCTTGATCCGAAATTGTTCCCTCGTTATCCAACAA
GAGGTGTACCCCAAGGAGAACGTTATAAGTGCATGAGTGTGGAAAGACATTAG
TGTATCTGCTCATCTCGTACAGCACCAACGAATCCACACTGGGAAAACCCCTATCT
CTGCACTGTCTGCGGGAAAGTCATTCTCACGATCCTCTTCTTATTGAACACCAGCGC
ATTACACGGGTGAGCGGCCGTATTGTCGGCAGTCGGGAAGAGCTTCTCCAG
TTGTGCAATCTTATTGCGCATCAGGGCGTGCACACGGGGAAATAAGCCCCACAAGTGT
GACGAATGTGGAAAAGCGTTAGTCAGTCAAACACTCAGGCCTCATTCAACACCAGCGAAT
CCATACAGGAGAGAACCGTATAAGTGTGAGAACATGCGATAAAATCCTCAGCCAAC
AACGCAGCCTGGTTATCATCAGAACGACACGCAGAACGTTAGGATATCTTGATTGAGCAT
CATGAATGTGACGCTTGCAGGGAGGCCTTAACGTAGGATATCTTGATTGAGCAT
AAAAAATTGCAACAGCTTGGATGCAATAGggatccctgtctgata

T7 ARCA forward primer:

TAATACGACTCACTATAGGGTAGGCCACCATGGCATC

Reverse primer:

GGATCCCTATTGCATCCAAGCTG

Primer sequences for qPCR assays and gblock sequence/primers for mRNA overexpression.